Immune globulin - CSL Behring

Drug Profile

Immune globulin - CSL Behring

Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; IgNextGen 10%; IgPro10; IgPro16; IgPro20; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF liquid; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF liquid; Tetagam P; Varicellon; Venimmun N; Vivaglobin

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL Behring
  • Developer Assistance Publique Hopitaux de Paris; CSL Behring; Rigshospitalet; University of Oxford
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Immune thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
  • Phase III Encephalitis; Renal transplant rejection
  • Phase II Skin and soft tissue infections
  • Phase I Spinal cord injuries
  • No development reported Motor neuron disease; Systemic lupus erythematosus

Most Recent Events

  • 09 Nov 2017 Preregistration for Chronic inflammatory demyelinating polyradiculoneuropathy in European Union (SC)
  • 09 Nov 2017 Preregistration for Chronic inflammatory demyelinating polyradiculoneuropathy in USA (SC)
  • 09 Nov 2017 Efficacy and adverse events data from the phase III PATH trial in Chronic inflammatory demyelinating polyradiculoneuropathy released by CSL Behring
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top